Enrollment in clinical trials is crucialto continued scientific discovery andimproved patient care.
David Dorr, MD, MS
Advertisement
Articles by David Dorr, MD, MS
Advertisement
Latest Updated Articles
- Reporting Only ‘Unanticipated’ AEs of Trial Drugs Would Reduce IRB Workload, But Would Patient Safety Suffer?
Published: November 1st 2006 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
2
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
3
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
4
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
5
